https://www.pharmaceutical-technology.com/data-insights/ixazomib-citrate-millennium-pharmaceuticals-relapsing-remitting-multiple-sclerosis-rrms-likelihood-of-approval-2/
Ixazomib citrate is under clinical development by Millennium Pharmaceuticals and currently in Phase II for Relapsing Remitting Multiple Sclerosis (RRMS).
ixazomib citratemillennium pharmaceuticalsrelapsing remittingmultiple sclerosis
https://www.rti.org/publication/quality-life-maintained-ixazomib-maintenance-post-transplant-newly-diagnosed-multiple-myeloma-tourma
Objectives Health-related quality of life (HRQoL) is particularly important during maintenance therapy (MT) in newly diagnosed multiple myeloma...
qualitylifemaintainedixazomibmaintenance
https://pubmed.ncbi.nlm.nih.gov/40998041/
Myeloma bone disease (MBD), a common complication in multiple myeloma (MM), causes increased risk of fractures leading to morbidity and impaired quality of...
bone remodelingixazomibtreatmentdualeffect
https://www.cancer.gov/research/participate/clinical-trials-search/v?id=NCI-2021-03038&r=1
Venetoclax, MLN9708 (Ixazomib Citrate) and Dexamethasone for the Treatment of Relapsed or Refractory Light Chain Amyloidosis
ixazomib citratevenetoclaxdexamethasonetreatment
https://www.mdpi.com/2072-6694/16/5/1024
Scarce data exist on double maintenance in transplant-eligible high-risk (HR) newly diagnosed multiple myeloma (NDMM) patients. This prospective phase 2 study...
ixazomiblenalidomidedexamethasoneirdtreatment